{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:27:49Z","timestamp":1787592469557,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40123-019-0177-7","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T10:02:26Z","timestamp":1553508146000},"page":"235-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part I: A Review of Disease Characterization and Morphological Associations"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4774-7614","authenticated-orcid":false,"given":"Mania","family":"Horani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq M.","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"177_CR1","doi-asserted-by":"publisher","first-page":"4263017","DOI":"10.1155\/2017\/4263017","volume":"2017","author":"AC Pedrosa","year":"2017","unstructured":"Pedrosa AC, Sousa T, Pinheiro-Costa J, et al. Treatment of neovascular age-related macular degeneration with anti-VEGF agents: predictive factors of long-term visual outcomes. J Ophthalmol. 2017;2017:4263017.","journal-title":"J Ophthalmol."},{"key":"177_CR2","doi-asserted-by":"publisher","first-page":"627674","DOI":"10.1155\/2015\/627674","volume":"2015","author":"V Tah","year":"2015","unstructured":"Tah V, Orlans HO, Hyer J, et al. Anti-VEGF therapy and the retina: an update. J Ophthalmol. 2015;2015:627674.","journal-title":"J Ophthalmol."},{"key":"177_CR3","unstructured":"American Academy of Ophthalmology Retina\/Vitreous Panel. Preferred practice pattern guidelines. Age-related macular degeneration. San Francisco: American Academy of Ophthalmology; 2015"},{"key":"177_CR4","first-page":"1001","volume":"9","author":"A Agarwal","year":"2015","unstructured":"Agarwal A, Rhoades WR, Hanout M, et al. Management of neovascular age-related macular degeneration: Current state-of-the-art care for optimizing visual outcomes and therapies in development. Clin Ophthalmol. 2015;9:1001\u2013155.","journal-title":"Clin Ophthalmol."},{"key":"177_CR5","first-page":"343","volume":"15","author":"DH Nguyen","year":"2013","unstructured":"Nguyen DH, Luo J, Zhang K, Zhang M. Current therapeutic approaches in neovascular age-related macular degeneration. Discov Med. 2013;15:343\u20138.","journal-title":"Discov Med."},{"key":"177_CR6","doi-asserted-by":"crossref","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8:CD005139.","DOI":"10.1002\/14651858.CD005139.pub3"},{"key":"177_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"177_CR8","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med."},{"key":"177_CR9","doi-asserted-by":"crossref","unstructured":"Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57\u201365.e5.","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"177_CR10","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122:2514\u201322.","journal-title":"Ophthalmology"},{"key":"177_CR11","doi-asserted-by":"crossref","unstructured":"Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399\u2013411.","DOI":"10.1016\/j.ophtha.2012.04.015"},{"key":"177_CR12","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258\u201367.","journal-title":"Lancet"},{"key":"177_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150\u201361.","journal-title":"Ophthalmology"},{"key":"177_CR14","doi-asserted-by":"crossref","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Seven-Up Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology. 2013;120(11):2292\u20132299.","DOI":"10.1016\/j.ophtha.2013.03.046"},{"key":"177_CR15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ophtha.2016.01.033","volume":"123","author":"RB Bhisitkul","year":"2016","unstructured":"Bhisitkul RB, Desai SJ, Boyer DS, Sadda SR, Zhang K. Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Ophthalmology. 2016;123:1269\u201377.","journal-title":"Ophthalmology"},{"key":"177_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ophtha.2014.07.046","volume":"122","author":"E Tanaka","year":"2015","unstructured":"Tanaka E, Chaikitmongkol V, Bressler SB, Bressler NM. Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:153\u201361.","journal-title":"Ophthalmology"},{"key":"177_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/IAE.0000000000000374","volume":"35","author":"L Xu","year":"2015","unstructured":"Xu L, Mrejen S, Jung JJ, et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina. 2015;35:176\u201386.","journal-title":"Retina"},{"issue":"6","key":"177_CR18","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ajo.2015.02.020","volume":"159","author":"C Sch\u00fctze","year":"2015","unstructured":"Sch\u00fctze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(6):1100\u201314.","journal-title":"Am J Ophthalmol"},{"key":"177_CR19","doi-asserted-by":"crossref","unstructured":"Chakravarthy U, Harding SP, Rogers CA, et al. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to inhibit VEGF in age-related choroidal Neovascularisation (IVAN). Health Technology Assessment, No. 19.78. Southampton: NIHR Journals Library; 2015.","DOI":"10.3310\/hta19780"},{"key":"177_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","volume":"124","author":"NS Abdelfattah","year":"2017","unstructured":"Abdelfattah NS, Al-Sheikh M, Pitetta S, et al. Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial. Ophthalmology. 2017;124:215\u201323.","journal-title":"Ophthalmology"},{"key":"177_CR21","doi-asserted-by":"crossref","unstructured":"Fan W, Abdelfattah NS, Uji A, et al. Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial. Graefes Arch Clin Exp Ophthalmol. 2018;256(3):511\u20138.","DOI":"10.1007\/s00417-017-3888-2"},{"key":"177_CR22","doi-asserted-by":"crossref","unstructured":"Hata M, Yamashiro K, Oishi A, et al. Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor injections for retinal angiomatous proliferation. Retina. 2017;37(11):2069\u20132077.","DOI":"10.1097\/IAE.0000000000001457"},{"key":"177_CR23","doi-asserted-by":"crossref","unstructured":"Zarubina AV, Gal-Or O, Huisingh CE, Owsley C, Freund KB. Macular atrophy development and subretinal drusenoid deposits in anti-vascular endothelial growth factor treated age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58(14):6038\u20136045.","DOI":"10.1167\/iovs.17-22378"},{"key":"177_CR24","doi-asserted-by":"crossref","unstructured":"Kuroda Y, Yamashiro K, Tsujikawa A, et al. Retinal pigment epithelial atrophy in neovascular age-related macular degeneration after ranibizumab treatment. Am J Ophthalmol. 2016;161:94\u2013103.","DOI":"10.1016\/j.ajo.2015.09.032"},{"key":"177_CR25","doi-asserted-by":"crossref","unstructured":"Thavikulwat AT, Jacobs-El N, Kim JS, et al. Evolution of geographic atrophy in participants treated with ranibizumab for neovascular age related macular degeneration. Ophthalmol Retina. 2017;1(1):34\u201341.","DOI":"10.1016\/j.oret.2016.09.005"},{"key":"177_CR26","doi-asserted-by":"crossref","unstructured":"Holz FG, Bindewald-Wittich A, Fleckenstein M, et al. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol. 2007;143:463\u2013472.","DOI":"10.1016\/j.ajo.2006.11.041"},{"key":"177_CR27","doi-asserted-by":"crossref","unstructured":"Sunness JS, Margalit E, Srikumaran D, et al. The long-term natural history of geographic atrophy from age-related macular degeneration. Enlargement of atrophy and implications for interventional clinical trials. Ophthalmology. 2007;114:271\u2013277.","DOI":"10.1016\/j.ophtha.2006.09.016"},{"key":"177_CR28","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1097\/IAE.0000000000000081","volume":"34","author":"M Young","year":"2014","unstructured":"Young M, Chui L, Fallah N, et al. Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Retina. 2014;34:1308\u201315.","journal-title":"Retina"},{"key":"177_CR29","doi-asserted-by":"crossref","unstructured":"Wons J, Wirth MA, Graf N, Becker MD, Michels S. Comparison of progression rate of retinal pigment epithelium loss in patients with neovascular age-related macular degeneration treated with ranibizumab and aflibercept. J Ophthalmol. 2017;7432739.","DOI":"10.1155\/2017\/7432739"},{"key":"177_CR30","doi-asserted-by":"crossref","unstructured":"Holz FG, Sadda SR, Staurenghi G, et al. Imaging protocols in clinical studies in advanced age-related macular degeneration: recommendations from classification of atrophy consensus meetings Ophthalmology. 2017;124:464\u2013478","DOI":"10.1016\/j.ophtha.2016.12.002"},{"key":"177_CR31","doi-asserted-by":"crossref","unstructured":"Sadda SR, Guymer R, Holz FG, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology. 2017;125(4):537\u201348.","DOI":"10.1016\/j.ophtha.2017.09.028"},{"issue":"3","key":"177_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","volume":"125","author":"M Fleckenstein","year":"2018","unstructured":"Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125(3):369\u201390.","journal-title":"Ophthalmology"},{"key":"177_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.ophtha.2015.03.027","volume":"122","author":"M Lindner","year":"2015","unstructured":"Lindner M, Boker A, Mauschitz MM, et al. Directional kinetics of geographic atrophy progression in age-related macular degeneration with foveal sparing. Ophthalmology. 2015;122:1356\u201365.","journal-title":"Ophthalmology"},{"issue":"5","key":"177_CR34","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","volume":"159","author":"RB Bhisitkul","year":"2015","unstructured":"Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the anchor, marina, and horizon studies: the seven-up study. Am J Ophthalmol. 2015;159(5):915\u201324.","journal-title":"Am J Ophthalmol."},{"key":"177_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000330420","volume":"226","author":"AP Gobel","year":"2011","unstructured":"Gobel AP, Fleckenstein M, Schmitz-Valckenberg S, et al. Imaging geographic atrophy in age-related macular degeneration. Ophthalmologica. 2011;226:182\u201390.","journal-title":"Ophthalmologica"},{"key":"177_CR36","doi-asserted-by":"crossref","unstructured":"Holz FG, Steinberg JS, Gobel A, et al. Fundus autofluorescence imaging in dry AMD: 2014 Jules Gonin lecture of the Retina Research Foundation. Graefes Arch Clin Exp Ophthalmol. 2015;253:7\u201316","DOI":"10.1007\/s00417-014-2858-1"},{"key":"177_CR37","doi-asserted-by":"publisher","first-page":"6440","DOI":"10.1167\/iovs.16-20265","volume":"57","author":"R Dolz-Marco","year":"2016","unstructured":"Dolz-Marco R, Gal-Or O, Freund KB. Choroidal thickness influences near-infrared reflectance intensity in eyes with geographic atrophy due to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016;57:6440\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"177_CR38","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1167\/iovs.06-0122","volume":"47","author":"CN Keilhauer","year":"2006","unstructured":"Keilhauer CN, Delori FC. Near-infrared autofluorescence imaging of the fundus: visualization of ocular melanin. Invest Ophthalmol Vis Sci. 2006;47:3556\u2013644.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"177_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000442784","volume":"56","author":"NK Waheed","year":"2016","unstructured":"Waheed NK, Moult EM, Fujimoto JG, Rosenfeld PJ. Optical coherence tomography angiography of dry age-related macular degeneration. Dev Ophthalmol. 2016;56:91\u2013100.","journal-title":"Dev Ophthalmol"},{"key":"177_CR40","doi-asserted-by":"crossref","unstructured":"Kvanta A, Casselholm de Salles M, Amren U, Bartuma H. Optical coherence tomography angiography of the foveal microvasculature in geographic atrophy. Retina. 2017;37:936\u2013942.","DOI":"10.1097\/IAE.0000000000001248"},{"key":"177_CR41","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.ophtha.2016.05.041","volume":"123","author":"M Pellegrini","year":"2016","unstructured":"Pellegrini M, Acquistapace A, Oldani M, et al. Dark atrophy: an optical coherence tomography angiography study. Ophthalmology. 2016;123:1879\u201386.","journal-title":"Ophthalmology"},{"key":"177_CR42","doi-asserted-by":"crossref","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group,\u00a0Martin DF,\u00a0Maguire MG,\u00a0et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119(7):1388\u201398.","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"177_CR43","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","volume":"122","author":"JE Grunwald","year":"2015","unstructured":"Grunwald JE, Pistilli M, Ying GS, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122:809\u201316.","journal-title":"Ophthalmology"},{"key":"177_CR44","unstructured":"Holz FG, Tuomi L, Ding B, Hopkins JJ. Development of atrophy in neovascular AMD treated with ranibizumab in the HARBOR study.\u00a0Invest Ophthalmol Vis Sci.\u00a02015;56 (7) (ARVO E- Abstract 890)."},{"key":"177_CR45","doi-asserted-by":"crossref","unstructured":"Busbee BG, Ho AC, Brown DM, et al.. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046\u201356.","DOI":"10.1016\/j.ophtha.2012.10.014"},{"key":"177_CR46","doi-asserted-by":"crossref","unstructured":"Ho AC, Busbee BG, Regillo CD, et al.. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181\u201392.","DOI":"10.1016\/j.ophtha.2014.05.009"},{"key":"177_CR47","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.ophtha.2016.07.007","volume":"123","author":"D Sarraf","year":"2016","unstructured":"Sarraf D, London NJS, Khurana RN, et al. Ranibizumab treatment for pigment epithelial detachment secondary to neovascular age-related macular degeneration post hoc analysis of the HARBOR study. Ophthalmology. 2016;123:2213\u201324.","journal-title":"Ophthalmology"},{"key":"177_CR48","doi-asserted-by":"crossref","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group,\u00a0Maguire MG,\u00a0Martin DF,\u00a0et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751\u201361.","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"177_CR49","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1097\/IAE.0b013e3181d50cbf","volume":"30","author":"M Engelbert","year":"2010","unstructured":"Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified \u2018treat and extend' dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina. 2010;30:1368\u201375.","journal-title":"Retina"},{"key":"177_CR50","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ajo.2003.09.042","volume":"137","author":"HE Grossniklaus","year":"2004","unstructured":"Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol. 2004;137:496\u2013503.","journal-title":"Am J Ophthalmol"},{"key":"177_CR51","first-page":"4977","volume":"55","author":"F Picton","year":"2014","unstructured":"Picton F, Muldrew KA, Reeves B, et al. Morphological features and determinants of new geographic atrophy developing in participants in the IVAN trial. Invest Ophthalmol Vis Sci. 2014;55:4977.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"177_CR52","unstructured":"Willoughby AS, Ying GS, Toth CA, et al. Subretinal hyper-reflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(9):1846.e5\u201353.e5."},{"key":"177_CR53","doi-asserted-by":"crossref","unstructured":"Lee JY, Folgar FA, Maguire MG, et al.. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2014;121(12):2423\u20132431.","DOI":"10.1016\/j.ophtha.2014.06.013"},{"issue":"2","key":"177_CR54","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ophtha.2014.08.035","volume":"122","author":"A Hariri","year":"2015","unstructured":"Hariri A, Nittala MG, Sadda SR. Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration. Ophthalmology. 2015;122(2):407\u201313.","journal-title":"Ophthalmology"},{"key":"177_CR55","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1097\/IAE.0b013e31828d6052","volume":"33","author":"K Moussa","year":"2013","unstructured":"Moussa K, Lee JY, Stinnett SS, Jaffe GJ. Spectral domain optical coherence tomography-determined morphologic predictors of age-related macular degeneration-associated geographic atrophy progression. Retina. 2013;33:1590\u20139.","journal-title":"Retina"},{"key":"177_CR56","doi-asserted-by":"crossref","unstructured":"Hariri MG, Nittala SR, Sadda. Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration. Ophthalmology. 2015;122:407\u2013413","DOI":"10.1016\/j.ophtha.2014.08.035"},{"key":"177_CR57","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ophtha.2010.08.010","volume":"118","author":"J Ho","year":"2011","unstructured":"Ho J, Witkin AJ, Liu J, et al. Documentation of intraretinal retinal pigment epithelium migration via high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2011;118:687\u201393.","journal-title":"Ophthalmology"},{"key":"177_CR58","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ophtha.2008.10.006","volume":"116","author":"SG Schuman","year":"2009","unstructured":"Schuman SG, Koreishi AF, Farsiu S, et al. Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography. Ophthalmology. 2009;116:488\u201396.","journal-title":"Ophthalmology"},{"key":"177_CR59","doi-asserted-by":"crossref","unstructured":"Folgar FA, Yuan EL, Sevilla MB, et al. Drusen volume and retinal pigment epithelium abnormal thinning volume predict 2-year progression of age-related macular degeneration. Ophthalmology 2016;123(1):39e1\u201350e1.","DOI":"10.1016\/j.ophtha.2015.09.016"},{"key":"177_CR60","doi-asserted-by":"crossref","unstructured":"Sleiman K, Veerappan M, Winter KP, et al. Optical coherence tomography predictors of risk for progression to non-neovascular atrophic age-related macular degeneration. Ophthalmology. 2017;124(12):1764\u20131777.","DOI":"10.1016\/j.ophtha.2017.06.032"},{"issue":"2","key":"177_CR61","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ophtha.2012.07.076","volume":"120","author":"M Kumar","year":"2013","unstructured":"Kumar M, Mrejen S, Fung AT, Marsiglia M, Loh BK, Spaide RF. Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration. Ophthalmology. 2013;120(2):334\u201341.","journal-title":"Ophthalmology"},{"issue":"11","key":"177_CR62","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00347-010-2159-y","volume":"107","author":"M Fleckenstein","year":"2010","unstructured":"Fleckenstein M, Wolf-Schnurrbusch U, Wolf S, von Strachwitz C, Holz FG, Schmitz-Valckenberg S. Imaging diagostics of geographic atrophy. Ophthalmologe. 2010;107(11):1007\u2013155.","journal-title":"Ophthalmologe."},{"issue":"4","key":"177_CR63","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000330420","volume":"226","author":"AP G\u00f6bel","year":"2011","unstructured":"G\u00f6bel AP, Fleckenstein M, Schmitz-Valckenberg S, Brinkmann CK, Holz FG. Imaging geographic atrophy in age-related macular degeneration. Ophthalmologica. 2011;226(4):182\u201390.","journal-title":"Ophthalmologica."}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-019-0177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-019-0177-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-019-0177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:03:13Z","timestamp":1724410993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-019-0177-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["177"],"URL":"https:\/\/doi.org\/10.1007\/s40123-019-0177-7","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]},"assertion":[{"value":"24 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}